- Home
- ALEC vs TARA Comparison
ALEC vs TARA Comparison
Compare ALEC & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEC
- TARA
- Stock Information
- Founded
- ALEC 2013
- TARA N/A
- Country
- ALEC United States
- TARA United States
- Employees
- ALEC N/A
- TARA N/A
- Industry
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALEC Health Care
- TARA Health Care
- Exchange
- ALEC Nasdaq
- TARA Nasdaq
- Market Cap
- ALEC 124.0M
- TARA 118.1M
- IPO Year
- ALEC 2019
- TARA N/A
- Fundamental
- Price
- ALEC $2.52
- TARA $3.11
- Analyst Decision
- ALEC Buy
- TARA Strong Buy
- Analyst Count
- ALEC 8
- TARA 7
- Target Price
- ALEC $4.50
- TARA $20.67
- AVG Volume (30 Days)
- ALEC 1.6M
- TARA 207.9K
- Earning Date
- ALEC 08-07-2025
- TARA 08-11-2025
- Dividend Yield
- ALEC N/A
- TARA N/A
- EPS Growth
- ALEC N/A
- TARA N/A
- EPS
- ALEC N/A
- TARA N/A
- Revenue
- ALEC $81,130,000.00
- TARA N/A
- Revenue This Year
- ALEC N/A
- TARA N/A
- Revenue Next Year
- ALEC $319.82
- TARA N/A
- P/E Ratio
- ALEC N/A
- TARA N/A
- Revenue Growth
- ALEC 46.77
- TARA N/A
- 52 Week Low
- ALEC $0.87
- TARA $1.60
- 52 Week High
- ALEC $6.37
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- ALEC 67.40
- TARA 48.81
- Support Level
- ALEC $2.03
- TARA $2.97
- Resistance Level
- ALEC $2.50
- TARA $3.33
- Average True Range (ATR)
- ALEC 0.25
- TARA 0.15
- MACD
- ALEC 0.04
- TARA -0.01
- Stochastic Oscillator
- ALEC 96.49
- TARA 38.89
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).